Artiva Biotherapeutics Prices Upsized $167M IPO

SAN DIEGO, July 18, 2024 — Artiva Biotherapeutics, Inc. (Nasdaq: ARTV), a biotechnology firm focused on developing cell therapies for autoimmune diseases and cancers, has announced the pricing of its enlarged initial public offering (IPO) of 13,920,000 shares at $12.00 per share. All shares are being offered by Artiva, with expected gross proceeds of around $167.0 million prior to underwriting discounts, commissions, and estimated offering expenses.

Moreover, Artiva has provided underwriters with a 30-day option to purchase an additional 2,088,000 shares at the IPO price, minus underwriting discounts and commissions. Trading of the shares is anticipated to begin on the Nasdaq Global Market on July 19, 2024, under the ticker symbol “ARTV.” The offering is projected to close on July 22, 2024, contingent on the satisfaction of standard closing conditions.

Jefferies, TD Cowen, and Cantor are acting as joint book-running managers for the offering, with Wedbush PacGrow and Needham & Company serving as co-lead managers. Registration statements for the securities sold in this offering were filed with the U.S. Securities and Exchange Commission (SEC) and became effective on July 18, 2024. The offering is being made solely via a prospectus that forms part of the registration statements.

Artiva Biotherapeutics, founded in 2019, aims to create effective, safe, and accessible cell therapies for patients suffering from severe autoimmune diseases and cancers. Its lead program, AlloNK®, is an off-the-shelf, cryopreserved NK cell therapy intended to boost the antibody-dependent cellular cytotoxicity effect of monoclonal antibodies to promote B-cell depletion. AlloNK® is currently undergoing clinical trials for the treatment of systemic lupus erythematosus, with or without lupus nephritis, and is also being tested in multiple autoimmune conditions in an investigator-initiated basket trial.

Artiva's pipeline also includes CAR-NK therapies aimed at both solid and hematologic cancers. The company emerged as a spin-out from GC Cell, formerly known as GC Lab Cell Corporation, a leading healthcare entity in the Republic of Korea. Through a strategic partnership, Artiva obtained exclusive global rights (excluding Asia, Australia, and New Zealand) to GC Cell’s NK cell manufacturing technologies and programs.

Artiva Biotherapeutics is dedicated to revolutionizing cell therapy, providing new treatment avenues for patients with challenging autoimmune diseases and cancers, through its innovative and accessible therapies.